Resumo

ELBERT, Alicia et al. Renal effects of GLP-1 agonists in type 2 diabetes. Medicina (B. Aires) [online]. 2022, vol.82, n.4, pp.576-590. ISSN 0025-7680.

The prevalence of type 2 diabetes mellitus (DM2) is increasing, generating a great impact both at individual and public health level. Nearly half of the patients with DM2 develop impaired renal function, so nephron-protection is highly important. The robust body of evidence that shifted the therapeutic focus from glycemic to cardio-renal metabolic therapy in DM2 led to the inclusion of new therapies with cardiovascular and renal benefits in international guidelines. Type 1 glucagon (GLP-1) receptor agonists have showed favorable effects on renal function and their potential protective actions are multifactorial, beyond glycemic control. These benefits have been demonstrated in efficacy and safety clini cal studies, as well as in cardiovascular outcomes and real-life studies. This comprehensive review describes the direct and indirect effects of these molecules, as well as evidence obtained from pivotal clinical (LEADER, SUSTAIN 6 and REWIND) and real-life studies demonstrating their beneficial effects on renal function, and also introduces expectations of future results from ongoing studies with renal endpoints.

Palavras-chave : GLP-1 receptor agonists; Type 2 diabetes mellitus; Renal outcomes.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )